STAAR Surgical Company (STAA) - Stock Analysis
Last updated: Apr 4, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
STAAR Surgical has a fresh revenue surprise and momentum: pre‑announced Q1 net sales above ~$90M drove a ~25% two‑day spike, and FDA expansion of EVO/EVO+ ICL indication (21–60 years) broadens its market. Shares are ~42% above their 21‑day mean, with strong volume and activist/institutional buying, making STAA a high‑velocity near‑term trade around the formal earnings release.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High liquidity • Negative margins • Elevated SG&A STAA has a strong balance sheet and ample liquidity but is weighed down by persistent operating losses, negative cash flow, and high opex that erode profitability.
Price Behavior
Key Price Behavior Insights: • Fresh last-month high • Near-term resistance • Support $17.5–18.6 Support Level: $17.47; secondary $18.3–$18.6 Resistance Level: $20.97–$22.50 (near ~$21.00) STAA rallied about 8.8% over the last month to trade at the top of its recent range, showing short-term bullish momentum but facing near-term resistance near $21 and risk of a pullback to $17.5–$18.6 if momentum fades.
Sentiment & News
Key News Insights: • Director accumulation • New institutional stake • Avg ~$18.4 price Director Broadwood bought ~615K STAAR shares mid‑March and Defender Capital opened a ~668K‑share stake, showing director accumulation and new institutional entry
AI Summary
STAA is now a turnaround/restructuring trade—activist-driven governance and insider buying materially increase the odds that deep opex cuts, China inventory normalization, and EVO+ commercialization will convert its ~75% gross margins into positive FCF, making execution credibility (not product fit) the decisive investment metric. Actionable triggers: sustained opex run-rate cuts, monthly FCF inflection and clear China/EVO+ revenue reads (and a price breakout above ~$21); failure on any of these preserves dilution/downside risk.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: pre‑announced Q1 net sales above ~$90M drove a ~25% two‑day spike, and FDA expansion of EVO/EVO+ ICL indication (21–60 years) broadens its market. Shares are ~42% above their 21‑day mean, with strong volume and activist/institutional buying, making STAA a high‑velocity near‑term trade around the formal earnings release. | Active | +0.0% |